Rubicon Research IPO Peer Comparison
Rubicon Research Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|
| Rubicon Research | 8.82 | 8.68 | 35.53 | | 29.02 | | Consolidated |
| Sun Pharmaceutical Industries | 45.60 | 45.60 | 300.99 | 34.98 | 16.16 | 5.31 | Consolidated |
| Aurobindo Pharma | 59.81 | 59.81 | 560.22 | 18.12 | 11.15 | 1.93 | Consolidated |
| Zydus Lifesciences | 44.97 | 44.97 | 238.05 | 21.83 | 21.34 | 4.12 | Consolidated |
| Strides Pharma Science | 45.05 | 45.05 | 277.34 | 18.27 | 17.21 | 2.97 | Consolidated |
| Dr. Reddy’s Laboratories | 67.89 | 67.79 | 402.78 | 18.05 | 18.53 | 3.04 | Consolidated |
| Alembic Pharmaceuticals | 29.68 | 29.68 | 264.09 | 30.43 | 11.63 | 3.41 | Consolidated |
| Lupin | 71.95 | 71.69 | 377.18 | 26.64 | 21.00 | 5.07 | Consolidated |
Notes:
- All the financial information for listed industry peers mentioned above is on an audited consolidated basis and sourced from the audited financial statements of the relevant companies for Fiscal 2025, as available on the websites of the Stock Exchanges.
- Details for our Company have been sourced/ calculated from the Restated Financial Information.
- Basic and diluted EPS refers to the Basic and diluted EPS sourced from the publicly available financial results of the listed industry peers for Fiscal 2025.
- P/E Ratio for the listed industry peers has been computed based on the closing market price September 30, 2025 of equity shares on BSE, divided by the Diluted EPS.
- Return on Net Worth is calculated as net profit or loss for the year/ period attributable to equity shareholders divided by average equity at the end of the year/ period.
- Net worth means the aggregate value of the paid-up equity share capital and other equity.
- Net Asset Value per share is calculated as net worth at the end of the year/ period / Weighted number of equity shares outstanding at the end of the year/ period.
